Literature DB >> 17477829

Farnesyl pyrophosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay.

J Fraser Glickman1, Andres Schmid.   

Abstract

A mix-and-read FlashPlate (PerkinElmer, Waltham, MA) assay for the enzyme farnesyl pyrophosphate (FPP) synthase (FPPS) was developed to rapidly measure both steps in the synthesis of FPP from dimethylallyl pyrophosphate (DMAPP). The assay used either DMAPP or geranyl pyrophosphate (GPP) and [(3)H]isopentenyl pyrophosphate ([(3)H]IPP) as substrates, and measured the FPPS-catalyzed conversion of these into [(3)H]FPP or [(3)H]GPP by capturing the products onto a phospholipid-coated scintillating microtiter plate and monitoring the product formation in a charge coupled device imager. The Michaelis-Menten parameters-k(cat) GPP (38/min), K(m) IPP (0.6 microM), and K(m) GPP (0.7 microM)-were consistent with previous studies using difficult phase separation techniques. The 50% inhibitory concentrations of various nitrogen-containing bisphosphonates (N-BPs) were determined and were also consistent with prior literature. Without precedent, weaker inhibition (5 microM) of the non-N-BPs was also detected. In preincubation studies, the potency of the N-BPs, and specifically zoledronate, increased slowly over time by 100-fold. This potency shift was reversed significantly by the inclusion of GPP with zoledronate. Zoledronate was uncompetitive with respect to IPP. Thus, these studies were consistent with prior structural and thermodynamic studies, and suggest a rapid formation of a lower-affinity complex between zoledronate and the GPP binding site, followed by the formation of a very tight complex of zoledronate and enzyme, which excludes further binding of GPP. Furthermore, one of the substrates from the first step in the catalytic cycle, DMAPP, was identified as a 1 microM inhibitor of the second step of the catalysis, suggesting that the FPP two-step synthesis is regulated by DMAPP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17477829     DOI: 10.1089/adt.2007.057

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  7 in total

1.  New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.

Authors:  D Fernández; R Ramis; J Ortega-Castro; R Casasnovas; B Vilanova; J Frau
Journal:  J Comput Aided Mol Des       Date:  2017-06-19       Impact factor: 3.686

2.  Mechanistic insights into protonation state as a critical factor in hFPPS enzyme inhibition.

Authors:  David Fernández; Joaquin Ortega-Castro; Laura Mariño; Joan Perelló; Juan Frau
Journal:  J Comput Aided Mol Des       Date:  2015-06-17       Impact factor: 3.686

3.  Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.

Authors:  Wolfgang Jahnke; Jean-Michel Rondeau; Simona Cotesta; Andreas Marzinzik; Xavier Pellé; Martin Geiser; André Strauss; Marjo Götte; Francis Bitsch; René Hemmig; Chrystèle Henry; Sylvie Lehmann; J Fraser Glickman; Thomas P Roddy; Steven J Stout; Jonathan R Green
Journal:  Nat Chem Biol       Date:  2010-08-15       Impact factor: 15.040

4.  Characterization of potential drug targets farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase in Schistosoma mansoni.

Authors:  Peter D Ziniel; Janish Desai; Cynthia L Cass; Craig Gatto; Eric Oldfield; David L Williams
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

5.  Development of a high-density assay for long-chain fatty acyl-CoA elongases.

Authors:  Hidefumi Kitazawa; Yasuhisa Miyamoto; Ken Shimamura; Akira Nagumo; Shigeru Tokita
Journal:  Lipids       Date:  2009-07-04       Impact factor: 1.880

6.  Cloning and characterization of bifunctional enzyme farnesyl diphosphate/geranylgeranyl diphosphate synthase from Plasmodium falciparum.

Authors:  Fabiana M Jordão; Heloisa B Gabriel; João M P Alves; Claudia B Angeli; Thaís D Bifano; Ardala Breda; Mauro F de Azevedo; Luiz A Basso; Gerhard Wunderlich; Emilia A Kimura; Alejandro M Katzin
Journal:  Malar J       Date:  2013-06-04       Impact factor: 2.979

Review 7.  Human isoprenoid synthase enzymes as therapeutic targets.

Authors:  Jaeok Park; Alexios N Matralis; Albert M Berghuis; Youla S Tsantrizos
Journal:  Front Chem       Date:  2014-07-22       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.